These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Fay JF; Farrens DL Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912 [TBL] [Abstract][Full Text] [Related]
27. Allosteric modulation of the cannabinoid CB1 receptor. Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085 [TBL] [Abstract][Full Text] [Related]
28. Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity. Fan H; Kotsikorou E; Hoffman AF; Ravert HT; Holt D; Hurst DP; Lupica CR; Reggio PH; Dannals RF; Horti AG Eur J Med Chem; 2009 Feb; 44(2):593-608. PubMed ID: 18511157 [TBL] [Abstract][Full Text] [Related]
29. Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis. Cichero E; Menozzi G; Spallarossa A; Mosti L; Fossa P J Mol Model; 2008 Dec; 14(12):1131-45. PubMed ID: 18696129 [TBL] [Abstract][Full Text] [Related]
30. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087 [TBL] [Abstract][Full Text] [Related]
31. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957 [TBL] [Abstract][Full Text] [Related]
32. Recent advances in CB1 cannabinoid receptor antagonists. Lange JH; Kruse CG Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959 [TBL] [Abstract][Full Text] [Related]
33. Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor. Scott CE; Ahn KH; Graf ST; Goddard WA; Kendall DA; Abrol R J Chem Inf Model; 2016 Jan; 56(1):201-12. PubMed ID: 26633590 [TBL] [Abstract][Full Text] [Related]
34. Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes. Grant PS; Kahlcke N; Govindpani K; Hunter M; MacDonald C; Brimble MA; Glass M; Furkert DP Bioorg Med Chem Lett; 2019 Nov; 29(21):126644. PubMed ID: 31564385 [TBL] [Abstract][Full Text] [Related]
35. A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives. Lazzari P; Distinto R; Manca I; Baillie G; Murineddu G; Pira M; Falzoi M; Sani M; Morales P; Ross R; Zanda M; Jagerovic N; Pinna GA Eur J Med Chem; 2016 Oct; 121():194-208. PubMed ID: 27240274 [TBL] [Abstract][Full Text] [Related]
36. Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists. Szabó G; Kiss R; Páyer-Lengyel D; Vukics K; Szikra J; Baki A; Molnár L; Fischer J; Keseru GM Bioorg Med Chem Lett; 2009 Jul; 19(13):3471-5. PubMed ID: 19457667 [TBL] [Abstract][Full Text] [Related]
37. Crystal Structure of the Human Cannabinoid Receptor CB Hua T; Vemuri K; Pu M; Qu L; Han GW; Wu Y; Zhao S; Shui W; Li S; Korde A; Laprairie RB; Stahl EL; Ho JH; Zvonok N; Zhou H; Kufareva I; Wu B; Zhao Q; Hanson MA; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ Cell; 2016 Oct; 167(3):750-762.e14. PubMed ID: 27768894 [TBL] [Abstract][Full Text] [Related]
38. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. Madsen MV; Peacock L; Werge T; Andersen MB J Psychopharmacol; 2006 Sep; 20(5):622-8. PubMed ID: 16533866 [TBL] [Abstract][Full Text] [Related]
39. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048 [TBL] [Abstract][Full Text] [Related]
40. The future of type 1 cannabinoid receptor allosteric ligands. Alaverdashvili M; Laprairie RB Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]